CAMBRIDGE, Mass., April 13, 2023 – Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today that the second Single Cell and AI in Medicine Symposium (SCAIM23) will take place virtually and in person at Boynton Yards in Somerville on May 4, 2023, from 12:00 pm to 5:30 pm ET.
Cellarity is pleased to announce the distinguished speakers and agenda for SCAIM23 to discuss the state of innovation at the intersection of single-cell analysis, AI, and biology and how this field is impacting drug discovery and the progress of medical science.
A select number of seats are available for the in-person event, register now to reserve your seat, click here. To register for the virtual event, click here.
#SCAIM23 Symposium Agenda
12:00PM – LUNCH & NETWORKING
12:30PM – Welcome and Opening Remarks
Fabrice Chouraqui, Pharm.D., CEO, Cellarity
Laurens Kruidenier, Ph.D., CSO, Cellarity
12:45PM – SESSION 1: Interpretation and Application of Data to Uncover New Biology
Session 1 Moderator: Chad Nusbaum, Ph.D., CTO, Cellarity
Scalable, High-Resolution Single-Nucleus Barcoding for Multi-Modal Spatial Genomics
Fei Chen, Ph.D., Broad Institute of MIT and Harvard
Dissecting Cell Identity Via Network Inference and In Silico Gene Perturbation
Samantha Morris, Ph.D., Washington University in St. Louis
Tracking Cells to Find the Origins of Disease
Sydney Shaffer, M.D., Ph.D., University of Pennsylvania
2:15PM – BREAK
2:30PM – SESSION 2: Applying High Dimensional Data and Machine Learning to the Drug Discovery Process
Session 2 Moderator: Diogo Camacho, Ph.D., VP Computational Biology, Cellarity
Defeating Cancer One Cell at a Time
Andrea Califano, Ph.D., Columbia University
Illuminating the Regulatory Logic of Tissues with Multiplexed Single-Cell Analysis
Zev Gartner, Ph.D., UC San Francisco
Artificial Intelligence Foundation for Therapeutic Science
Marinka Zitnik, Ph.D., Harvard University
4:00PM – Break
4:15PM – SESSION 3: Trends in Industry
Session 3 Moderator: Kat Guillen, Ph.D., Head of Strategy, Cellarity
Tommaso Biancalani, Ph.D., Genentech
Jonah Cool, Ph.D., Chan Zuckerberg Initiative
Enoch Huang, Ph.D., Pfizer
Laurens Kruidenier, Ph.D., Cellarity
5:00PM – KEYNOTE
Competing in the Age of AI: Implications for the Biopharma Industry
Karim Lakhani, Ph.D., Harvard Business School
5:30PM – RECEPTION
For more info, follow Cellarity on Twitter and LinkedIn. Hashtag for the symposium is #SCAIM23.
About Cellarity
Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 500 billion genomics data points to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.
MEDIA CONTACT: Jessica Yingling, Ph.D., press@cellarity.com